Share this article
Share this article
NIEL, Belgium, Aug. 3, 2021 /PRNewswire/ eTheRNA immunotherapies NV ( eTheRNA or the Company ), a clinical-stage company developing mRNA-based immunotherapies for the treatment of cancer and infectious diseases, today announces the opening of its new subsidiary, eTheRNA Asia Limited ( eTheRNA Asia ), with offices located in the Sheung Wan area of Hong Kong.
The Asia-Pacific region is growing in importance in the global healthcare sector and this new subsidiary will serve as a focus for eTheRNA s increasing commercial activities in this area. In particular, eTheRNA Asia will focus on supporting business and investor relations in China and especially the relationship between eTheRNA and its strategic partner, China Grand Pharmaceutical and Healthcare Holdings Ltd ( CGP ). CGP and eTheRNA s relationship is centred on their joint venture company, Nanjing AuroRNA Biotechnology Company Limited.